Guardant Health supports Prostate Cancer Awareness Month
Home » Guardant Health supports Prostate Cancer Awareness Month

GH AMEA on Social MediaGuardant Health supports Prostate Cancer Awareness Month
Guardant Health supports Prostate Cancer Awareness Month
Guardant Health supports Prostate Cancer Awareness Month
LinkedIn

September marks Prostate Cancer Awareness Month. Check out this study (https://jitc.bmj.com/content/8/2/e001065) which concluded that the use of a well-validated cfDNA NGS liquid biopsy such as the Guardant360®️ test to identify metastatic prostate cancer patients with MSI-H is feasible in clinical practice and may overcome the obstacles associated with prostate cancer tumor tissue for timely genomic assessment.

Speak to your doctor today about comprehensive genomic testing with a simple blood draw. Visit us at https://www.guardanthealthamea.com/resources/ to find out how the Guardant360 test can help to guide treatment decisions for patients with advanced stage prostate cancer.

Reference: Barata P, Agarwal N, Nussenzveig R, et alClinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNAJournal for ImmunoTherapy of Cancer 2020;8:e001065. doi: 10.1136/jitc-2020-001065

#guardanthealthamea #guardanthealth #guardant360 #prostatecancer #liquidbiopsy #comprehensivegenomicprofiling #precisiononcology

Message us